Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

[68Ga]Ga-FAPI-46

Phase 2

NNantes University Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cardiac AmyloidosisNot yet recruiting

Cardiac AmyloidosisPhase 2

Not yet recruiting

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Cardiac Amyloidosis

NCT07549841

Clinical

Trials by Indication[1]

Cardiac Amyloidosis1 trial

Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis

Not yet recruiting·NNantes University Hospital·Phase 2·NCT07549841·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [68Ga]Ga-FAPI-46. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [68Ga]Ga-FAPI-46. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nantes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNantes University Hospital

Related News